NeuroMab™ Anti-CXCR4 BBB Shuttle Antibody(NRZP-1022-ZP3815)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

Inhib; In Vitro

Relevant Diseases

Alzheimer's Disease; Parkinson's Disease

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

CXCR4

Official Name

CXCR4

Full Name

C-X-C Motif Chemokine Receptor 4

Alternative Names

NR2F1; BBOAS; BBSOAS; COUP-TFI; EAR-3; EAR3; ERBAL3; NR2F2; SVP44; TCFCOUP1; TFCOUP1; nuclear receptor subfamily 2 group F member 1; COUPTF1

Product Pictures

FuncS

Figure 1 is a graph showing that single chain antibodies Ab124 and Ab125 can inhibit SDF-1-induced chemotaxis in the human breast cancer cell line MDA-MB-231.

Block

Figure 2 is a graph showing that both scFvs directed against human CCR5 Loop 6 are able to block the binding of MIP-la to CCR5 on human monocyte-derived macrophages.

Figure 3 shows a Western blot of human CCR5 loop 6 of human macrophage-expressed CCR5 probed with scFv.

FuncS

Figure 4A shows HIV-1 reverse transcriptase (RT) activity in HIV-1 infected human monocyte cultures in the presence or absence of antibodies at days 4, 8 and 12 post infection, respectively.

FuncS

Figure 4B shows HIV-1 reverse transcriptase (RT) activity in cultures of human monocytes infected with HIV-1 in the presence or absence of antibodies at days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 4C shows HIV-1 reverse transcriptase (RT) activity in human monocyte cultures infected with HIV-1 in the presence or absence of antibodies at days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 5A shows the viability of human monocyte cultures infected with HIV-1 in the presence or absence of antibodies on days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 5B shows the viability of human monocyte cultures infected with HIV-1 in the presence or absence of antibodies on days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 5C shows the viability of human monocyte cultures infected with HIV-1 in the presence or absence of antibodies on days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 6A shows HIV-1 reverse transcriptase (RT) activity in cultures of human monocytes infected with HIV-1 in the presence or absence of antibodies at days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 6B shows HIV-1 reverse transcriptase (RT) activity in human monocyte cultures infected with HIV-1 in the presence or absence of antibodies at days 4, 8 and 12 post-infection, respectively.

FuncS

Figure 6C shows HIV-1 reverse transcriptase (RT) activity in human monocyte cultures infected with HIV-1 in the presence or absence of antibodies at days 4, 8 and 12 post-infection, respectively.

Publications